Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4044)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 14, 2023 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1614-1626 [PMID: 36970591 DOI: 10.3748/wjg.v29.i10.1614] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i10/1614.htm |
| Number | Citing Articles |
| 1 |
Jiayi Wu, Junyi Wu, Shuqun Li, Mengchao Luo, Zhenxin Zeng, Yinan Li, Yangkai Fu, Han Li, Deyi Liu, Xiangye Ou, Zhongtai Lin, Shaoming Wei, Maolin Yan. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics. BioScience Trends 2024; 18(1): 42 doi: 10.5582/bst.2023.01326
|
| 2 |
Lei Wang, Li Lin, Wei Zhou. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis. Pharmacology & Therapeutics 2024; 257: 108634 doi: 10.1016/j.pharmthera.2024.108634
|
| 3 |
Jingwen Feng, Yi Zhao, Lin Zhai, Jingxu Zhou. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine 2024; 103(18): e38037 doi: 10.1097/MD.0000000000038037
|
| 4 |
Junning Liu, Song Wei, Linfeng Yang, Jiahui Yu, Duan Yan, Pengsheng Yi. Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology 2023; 149(15): 14451 doi: 10.1007/s00432-023-05231-x
|
| 5 |
Christina G. Dalzell, Amy C. Taylor, Sarah B. White. New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma. Cancers 2023; 15(24): 5749 doi: 10.3390/cancers15245749
|
| 6 |
YiFeng Liang, LiMing Gan, DeJin Zeng, LangHua Lin, ZheKun Xiong, FangLian Liao, ALing Wang. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. Clinical and Translational Oncology 2024; doi: 10.1007/s12094-024-03458-9
|